|
1
|
Wattad M, Weber D, Döhner K, Krauter J,
Gaidzik VI, Paschka P, Heuser M, Thol F, Kindler T, Lübbert M, et
al: Impact of salvage regimens on response and overall survival in
acute myeloid leukemia with induction failure. Leukemia.
31:1306–1313. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kelly E and Russell SJ: History of
oncolytic viruses: Genesis to genetic engineering. Mol Ther.
15:651–659. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Berchtold S, Lampe J, Weiland T, Smirnow
I, Schleicher S, Handgretinger R, Kopp HG, Reiser J, Stubenrauch F,
Mayer N, et al: Innate immune defense defines susceptibility of
sarcoma cells to measles vaccine virus-based oncolysis. J Virol.
87:3484–3501. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Russell SJ, Peng KW and Bell JC: Oncolytic
virotherapy. Nat Biotechnol. 30:658–670. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cattaneo R, Miest T, Shashkova EV and
Barry MA: Reprogrammed viruses as cancer therapeutics: Targeted,
armed and shielded. Nat Rev Microbiol. 6:529–540. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Aref S, Bailey K and Fielding A: Measles
to the rescue: A rview of oncolytic measles virus. Viruses.
8:82016. View
Article : Google Scholar
|
|
7
|
Takeuchi O and Akira S: MDA5/RIG-I and
virus recognition. Curr Opin Immunol. 20:17–22. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hornung V, Ellegast J, Kim S, Brzózka K,
Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M, et al:
5'-Triphosphate RNA is the ligand for RIG-I. Science. 314:994–997.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Darnell JE Jr, Kerr IM and Stark GR:
Jak-STAT pathways and transcriptional activation in response to
IFNs and other extracellular signaling proteins. Science.
264:1415–1421. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Berghäll H, Sirén J, Sarkar D, Julkunen I,
Fisher PB, Vainionpää R and Matikainen S: The interferon-inducible
RNA helicase, mda-5, is involved in measles virus-induced
expression of antiviral cytokines. Microbes Infect. 8:2138–2144.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Childs K, Stock N, Ross C, Andrejeva J,
Hilton L, Skinner M, Randall R and Goodbourn S: mda-5, but not
RIG-I, is a common target for paramyxovirus V proteins. Virology.
359:190–200. 2007. View Article : Google Scholar
|
|
12
|
Graepler F, Lemken ML, Wybranietz WA,
Schmidt U, Smirnow I, Gross CD, Spiegel M, Schenk A, Graf H, Lauer
UA, et al: Bifunctional chimeric SuperCD suicide gene -YCD: YUPRT
fusion is highly effective in a rat hepatoma model. World J
Gastroenterol. 11:6910–6919. 2005. View Article : Google Scholar
|
|
13
|
Pol J, Vacchelli E, Aranda F, Castoldi F,
Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J,
Spisek R, et al: Trial Watch: Immunogenic cell death inducers for
anticancer chemotherapy. OncoImmunology. 4:e10088662015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang LF, Tan DQ, Jeyasekharan AD, Hsieh
WS, Ho AS, Ichiyama K, Ye M, Pang B, Ohba K, Liu X, et al:
Combination of vaccine-strain measles and mumps virus
synergistically kills a wide range of human hematological cancer
cells: Special focus on acute myeloid leukemia. Cancer Lett.
354:272–280. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kaerber G: Beitrag zur kollektiven
Behandlung pharmak-ologischer Reihenversuche. Naunyn-Schmiedeberg's
Arch Pharmacol. 162:480–483. 1931.In German. View Article : Google Scholar
|
|
17
|
Spearman C: The method of 'right and wrong
cases' ('constant stimuli') without Gauss's formulae. Br J Psychol.
2:227–242. 1908.
|
|
18
|
Hashiguchi T, Maenaka K and Yanagi Y:
Measles virus hemagglutinin: Structural insights into cell entry
and measles vaccine. Front Microbiol. 2:2472011. View Article : Google Scholar
|
|
19
|
Naniche D, Varior-Krishnan G, Cervoni F,
Wild TF, Rossi B, Rabourdin-Combe C and Gerlier D: Human membrane
cofactor protein (CD46) acts as a cellular receptor for measles
virus. J Virol. 67:6025–6032. 1993.PubMed/NCBI
|
|
20
|
Dörig RE, Marcil A, Chopra A and
Richardson CD: The human CD46 molecule is a receptor for measles
virus (Edmonston strain). Cell. 75:295–305. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ribas A, Dummer R, Puzanov I, VanderWalde
A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J,
Fernandez E, et al: Oncolytic virotherapy promotes intratumoral T
cell infiltration and improves anti-PD-1 immunotherapy. Cell.
170:1109–1119. e11102017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Z, Ravindranathan R, Kalinski P, Guo
ZS and Bartlett DL: Rational combination of oncolytic vaccinia
virus and PD-L1 blockade works synergistically to enhance
therapeutic efficacy. Nat Commun. 8:147542017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cervera-Carrascon V, Siurala M, Santos JM,
Havunen R, Tähtinen S, Karell P, Sorsa S, Kanerva A and Hemminki A:
TNFα and IL-2 armed adenoviruses enable complete responses by
anti-PD-1 checkpoint blockade. OncoImmunology. 7:e14129022018.
View Article : Google Scholar
|
|
24
|
Binz E and Lauer UM: Chemovirotherapy:
Combining chemotherapeutic treatment with oncolytic virotherapy.
Oncolytic Virother. 4:39–48. 2015.PubMed/NCBI
|
|
25
|
Binz E, Berchtold S, Beil J, Schell M,
Geisler C, Smirnow I and Lauer UM: Chemovirotherapy of pancreatic
adenocarcinoma by combining oncolytic vaccinia virus GLV-1h68 with
nab-paclitaxel plus gemcitabine. Mol Ther Oncolytics. 6:10–21.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mahalingam D, Goel S, Aparo S, Patel Arora
S, Noronha N, Tran H, Chakrabarty R, Selvaggi G, Gutierrez A,
Coffey M, et al: A phase II study of pelareorep (REOLYSIN®) in
combination with gemcitabine for patients with advanced pancreatic
adenocarcinoma. Cancers (Basel). 10:102018. View Article : Google Scholar
|
|
27
|
Noll M, Berchtold S, Lampe J, Malek NP,
Bitzer M and Lauer UM: Primary resistance phenomena to oncolytic
measles vaccine viruses. Int J Oncol. 43:103–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pol J, Buqué A, Aranda F, Bloy N, Cremer
I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, et al:
Trial Watch-Oncolytic viruses and cancer therapy. OncoImmunology.
5:e11177402015. View Article : Google Scholar
|
|
29
|
Cloughesy TF, Landolfi J, Vogelbaum MA,
Ostertag D, Elder JB, Bloomfield S, Carter B, Chen CC, Kalkanis SN,
Kesari S, et al: Durable complete responses in some recurrent
high-grade glioma patients treated with Toca 511 + Toca FC.
Neuro-oncol. 20:1383–1392. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pardee TS, Gomes E, Jennings-Gee J,
Caudell D and Gmeiner WH: Unique dual targeting of thymidylate
synthase and topoisomerase1 by FdUMP[10] results in high efficacy
against AML and low toxicity. Blood. 119:3561–3570. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
der Deutschen J: Suicide gene-armed
measles vaccine virus for the treatment of AML. In: Proceedings of
the Annual Meeting of the German Society for Haematology and
Medical Oncology (DGHO) in Stuttgart. Oncol Res Treat. 40(Suppl 3):
1–308. 2017.
|
